The Fat Signal: How 2-AG Rewires Obesity, Inflammation and Metabolism

Obesity has long been framed as a simple arithmetic problem: too many calories in, too few burned. But a new review published in Molecular Biology Reports argues that this framing misses a crucial molecular player. Shilpa Kumari, Biswanath Nayak and Rahul Deshmukh of the Department of Pharmacology at Central University of Punjab, Bathinda, synthesize evidence that 2-arachidonoylglycerol, or 2-AG, one of the body’s two principal endocannabinoids, acts as a signaling hub that connects appetite control in the brain to fat storage, insulin action, mitochondrial function and inflammation throughout the body. Their central claim is provocative: 2-AG is not merely a consequence of obesity but an active mediator of its pathogenesis, and levels of this lipid messenger are consistently elevated in obese states, where they help orchestrate the multi-organ dysfunction that makes obesity so difficult to reverse.

2-AG belongs to the endocannabinoid system, a lipid signaling network composed of endogenous cannabinoids, their G protein-coupled receptors, chiefly cannabinoid receptor type 1 (CB1) and type 2 (CB2), and the enzymes that synthesize and degrade these messengers. Unlike classical neurotransmitters, endocannabinoids are synthesized on demand from membrane lipids and travel backward across synapses to modulate neuronal firing. 2-AG is produced primarily by diacylglycerol lipase (DAGL) from membrane diacylglycerol precursors and is rapidly hydrolyzed by monoacylglycerol lipase (MAGL). This tight enzymatic control means that 2-AG signaling is exquisitely sensitive to metabolic state, dietary composition and tissue-specific enzyme expression, a property that becomes pathological when the system is chronically overdriven.

The review’s most striking thread concerns the brain. In the hypothalamus, CB1 receptors are densely expressed on appetite-regulating circuits, including the NPY/AgRP neurons of the arcuate nucleus that drive hunger. Endocannabinoid signaling at these synapses is orexigenic, meaning it promotes food intake, and it interacts with hormonal signals such as ghrelin and orexin. Studies cited in the review show that the orexigenic effect of ghrelin is mediated through central activation of the endocannabinoid system, and that orexin-A can repress satiety-inducing POMC neurons via stimulation of endocannabinoid signaling, contributing to weight gain. In obesity, peripheral endocannabinoid signaling in the gut also inhibits satiation signaling, blunting the normal gut-brain feedback that terminates a meal. The result is a feed-forward loop: more 2-AG, more reward-driven and hyperphagic eating, more adiposity, and again more 2-AG.

Diet itself may fuel this loop. One landmark study highlighted in the review found that dietary linoleic acid, abundant in modern processed foods, elevates endogenous 2-AG and anandamide levels and induces obesity in animal models. Because 2-AG is synthesized from arachidonic acid-containing membrane lipids, the fatty acid composition of the diet can directly shape the tone of endocannabinoid signaling. This provides a mechanistic bridge between the industrial food environment and the neurobiology of overeating, and it suggests that the obesity pandemic is not simply a failure of willpower but a biochemical consequence of altered lipid substrates reaching the enzymes that manufacture endocannabinoids.

Beyond the brain, the review details how 2-AG acts on adipose tissue, liver, skeletal muscle and pancreas through CB1 and, in immune cells, CB2 receptors. In adipocytes, endocannabinoid signaling promotes adipogenesis, the formation and enlargement of fat cells, and stimulates glucose uptake via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. In the liver, activation of hepatic CB1 receptors stimulates fatty acid synthesis and is required for the development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. Conversely, CB1 receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity, while peripheral CB1 inverse agonism reduces obesity by reversing leptin resistance. These findings establish the endocannabinoid system as a genuine peripheral regulator of energy storage, not just a central appetite switch.

At the molecular level, the review maps how 2-AG signaling intersects with canonical metabolic pathways. CB1 activation couples to the insulin/PI3K/AKT axis, with evidence that CB1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 (FOXO1) activity in obese mice. It also modulates AMP-activated protein kinase (AMPK), the cellular energy sensor: CB1 blockade has been shown to ameliorate hepatic fat infiltration and inflammation while increasing the Nrf2-AMPK pathway in diabetic rat models, and the CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity. Interactions with peroxisome proliferator-activated receptors (PPARs) and the inflammatory transcription factor NF-κB further entangle endocannabinoid tone with lipid metabolism and inflammation. The review argues that these convergences allow elevated 2-AG to amplify metabolic dysfunction across multiple pathways simultaneously, which helps explain why obesity is so often accompanied by insulin resistance, fatty liver disease and chronic low-grade inflammation as a coherent syndrome rather than as separate conditions.

Mitochondria emerge as a particularly intriguing nexus. Endocannabinoid signaling influences mitochondrial biogenesis and oxidative metabolism in adipocytes: CB1 blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white fat cells and can induce transdifferentiation of white adipocytes toward a brown fat phenotype, which burns energy rather than storing it. CB1 receptors also mediate depot-specific effects on differentiation, inflammation and oxidative metabolism in different white adipose tissue depots. Because impaired mitochondrial function in muscle and fat is a hallmark of insulin resistance and lipotoxicity, the review suggests that 2-AG-driven suppression of mitochondrial oxidative capacity may be a key mechanism linking endocannabinoid overactivity to the metabolic inflexibility observed in obesity and type 2 diabetes.

Inflammation is the third pillar of the review’s argument. Obese adipose tissue is infiltrated by macrophages, and the polarization of these immune cells toward pro-inflammatory M1 states drives systemic insulin resistance. Here the two cannabinoid receptors diverge sharply. CB1 signaling in macrophages appears to worsen metabolic inflammation: decreasing CB1 signaling in Kupffer cells, the liver’s resident macrophages, improves insulin sensitivity in obese mice, and CB1 blockade attenuates adipose tissue inflammation through microRNA-mediated regulation of macrophage signaling. CB2, by contrast, is largely anti-inflammatory. CB2 agonists such as JWH-133 attenuate chronic inflammation by restraining M1 macrophage polarization via the Nrf2/HO-1 pathway in diet-induced obese mice, and CB2 activation has been implicated in reducing fat storage and promoting adipose browning. The review, which builds on the group’s earlier work on CB2 in hepatic steatosis and fibrosis, frames selective CB2 activation and peripheral CB1 blockade as complementary pharmacological strategies.

The therapeutic history of this field is cautionary but instructive. The CB1 antagonist SR141716 (rimonabant) produced robust weight loss and improved metabolic parameters in diet-induced obese mice and was briefly approved in Europe, but it was withdrawn after psychiatric adverse events, a consequence of blocking CB1 receptors in the brain. The lesson, the authors argue, is that future therapies must target the periphery or the enzymes that control 2-AG levels rather than central receptors wholesale. Inhibitors of DAGL, the synthetic enzyme for 2-AG, and MAGL, its degradative enzyme, offer such an approach, and DAGL inhibition has already shown efficacy in preclinical models of excessive reward-driven intake. Peripherally restricted CB1 antagonists and CB2 agonists, including plant-derived compounds such as beta-caryophyllene, a dietary CB2 ligand, represent additional avenues. Even exercise appears to retune the endocannabinoid system in high-fat diet-induced obesity, suggesting lifestyle interventions may partly work through this axis.

The review is careful to distinguish direct evidence for 2-AG from extrapolation, noting that much of the mechanistic data comes from rodent models and that human studies, such as the finding that plasma 2-AG is a biomarker of age- and menopause-related insulin resistance and dyslipidemia in lean individuals, remain limited. Yet the convergence of evidence across the gut-brain-adipose axis is compelling. If 2-AG truly sits at the crossroads of appetite, adipogenesis, insulin signaling, mitochondrial function and inflammation, then modulating the 2-AG/endocannabinoid axis with tissue-selective tools could yield the next generation of obesity treatments, ones that address the disease’s biology rather than only its energy arithmetic. As obesity reaches pandemic proportions in every household, decoding this fat-derived signal may prove one of the most consequential tasks in metabolic medicine.

Subject of Research: The role of the endocannabinoid 2-arachidonoylglycerol in obesity, inflammation and metabolic dysfunction

Article Title: Beyond energy balance: 2-arachidonoylglycerol at the crossroads of obesity, inflammation, and metabolic dysfunction

Article References: Kumari, S., Nayak, B., & Deshmukh, R. (2026). Beyond energy balance: 2-arachidonoylglycerol at the crossroads of obesity, inflammation, and metabolic dysfunction. Molecular Biology Reports, 53(1), Article 1706. https://doi.org/10.1007/s11033-026-12909-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12909-1

Keywords: 2-arachidonoylglycerol, endocannabinoid system, obesity, CB1 receptor, CB2 receptor, inflammation, insulin resistance, hypothalamus, adipose tissue, mitochondria, MAGL, metabolic dysfunction